Membranous Nephropathy (MN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Membranous Nephropathy (MN), also called membranous glomerulopathy, is a type of glomerular disease resulting in nephrotic syndrome. It is defined by the presence of significant proteinuria (>3.5 g/day) and the manifestation of clinical symptoms such as peripheral edema, hypertension, frothy urine, and thromboembolic events. MN can be classified into primary (75-80%) and secondary (20-25%) forms. Primary MN is often idiopathic but may be associated with antibodies against the phospholipase A2 receptor (PLA2R) antigen (70-80%), neural epidermal growth factor-like 1 (NELL) (15-20%), thrombospondin (1-5%), neutral endopeptidase (NEP), or exostosin (EXT1/EXT2). Secondary MN is linked to infections, neoplasms, drugs, heavy metal poisoning, autoimmune diseases, and other miscellaneous factors. The formation of antigen-antibody complexes between the glomerular basement membrane and podocytes causes MN. These complexes, which primarily consist of immunoglobulin IgG4, complement C3, and C5b-C9 membrane attack complexes (MAC), activate the complement system and generate proteases, cytokines, and oxidants that result in cellular and tissue damage, leading to proteinuria. MN must be differentiated from other nephrotic syndromes that present with similar symptoms. Some differential diagnoses for MN include focal segmental glomerulosclerosis, minimal change disease, diabetic nephropathy, IgA nephropathy, and membranoproliferative glomerulonephritis. The management of MN involves symptomatic treatment with diuretics, statins, angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), systemic anticoagulant therapy, antihypertensives, and dietary salt restriction. Approximately one-third of patients will respond to these conservative measures, while another one-third will require additional treatments.

·       The estimated incidence of membranous nephropathy in the USA is 12 cases per one million individuals. MN is less common in children and is primarily due to secondary causes..

Thelansis’s “Membranous Nephropathy (MN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Membranous Nephropathy (MN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Membranous Nephropathy (MN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Membranous Nephropathy (MN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Membranous Nephropathy (MN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032